Febrile neutropenia (FEN) is a leading complication of intensive chemotherapy. With this
prospective randomized study, the authors aimed to compare the effectiveness of sulbactam …

Background ECIL-2021 recommends discontinuing empirical antibiotic therapy (EAT) in
febrile-neutropenic children after 72 h of treatment and at least 24–48 h of apyrexia in the …

Febrile neutropenia (FN) is only second to chemotherapy administration as a cause of
hospital admission during treatment for cancer. As FN may signify serious or life‐threatening …

Background A better understanding of drivers of treatment costs may help identify effective
cost containment strategies and prioritize resources. We aimed to develop a method for …

Abstract Background The Paediatric Oncology Centres (POCs) treating childhood cancer in
South East England produce unified supportive care guidelines for use in the secondary …

GIL-VELOZ, Mariana et al. Early discharge of pediatric patients with cancer, fever, and
neutropenia with low-risk of systemic infection. Bol. Med. Hosp. Infant. Mex.[online]. 2018 …

BACKGROUND The objective of this study was to assess the feasibility of empiric, oral,
outpatient quinolone monotherapy in 40 adult patients with fever and neutropenia who were …

Objective: To compare the use of intravenous vs. oral antibiotic therapy. Methods: All febrile
neutropenic patients younger than 18 years old with low risk of complications and receiving …

Introduction Many febrile neutropenia (FN) episodes are low risk (LR) for severe outcomes
and can safely receive less aggressive management and early hospital discharge. Validated …

vol. 29 número2 Susceptibilidad a azoles y anfotericina B de aislados de Candida spp:
Experiencia de una red de salud universitaria, entre 2004 y 2010 Bacteriemia en pacientes …